{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:00:48Z","timestamp":1783029648599,"version":"3.54.6"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00115-019-0783-6","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T11:02:35Z","timestamp":1565348555000},"page":"932-937","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Neue Slow-release-Buprenorphinformulierungen zur Optimierung der Opioidsubstitution","New slow-release buprenorphine formulations for optimization of opioid substitution"],"prefix":"10.1007","volume":"90","author":[{"given":"Michael","family":"Soyka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Pogarell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,9]]},"reference":[{"key":"783_CR1","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s12325-016-0472-9","volume":"34","author":"M Albayaty","year":"2017","unstructured":"Albayaty\u00a0M, Linden\u00a0M, Olsson\u00a0H, Johnsson\u00a0M, Strandgarden\u00a0K, Tiberg\u00a0F (2017) Pharmacokinetic evaluation of one-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM 2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label phase 1 study. Adv Ther 34:560\u2013575","journal-title":"Adv Ther"},{"key":"783_CR2","first-page":"CD005031","volume":"4","author":"L Amato","year":"2008","unstructured":"Amato\u00a0L, Minozzi\u00a0S, Davoli\u00a0M, Vecchi\u00a0S, Ferri\u00a0MM, Mayet\u00a0S (2008) Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 4:CD5031","journal-title":"Cochrane Database Syst Rev"},{"key":"783_CR3","first-page":"CD005031","volume":"9","author":"L Amato","year":"2011","unstructured":"Amato\u00a0L, Minozzi\u00a0S, Davoli\u00a0M, Vecchi\u00a0S (2011) Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 9:CD5031","journal-title":"Cochrane Database Syst Rev"},{"key":"783_CR4","first-page":"CD004147","volume":"10","author":"L Amato","year":"2011","unstructured":"Amato\u00a0L, Minozzi\u00a0S, Davoli\u00a0M, Vecchi\u00a0S (2011) Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 10:CD4147","journal-title":"Cochrane Database Syst Rev"},{"key":"783_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/2045125316681984","volume":"7","author":"P Barnwal","year":"2017","unstructured":"Barnwal\u00a0P, Das\u00a0S, Mondal\u00a0S, Ramasamy\u00a0A, Maiti\u00a0T, Saha\u00a0A (2017) Probuphine\u00ae (buprenorphine implant): a\u00a0promising candidate in opioid dependence. Ther Adv Psychopharmacol 7:119\u2013134. \n                    https:\/\/doi.org\/10.1177\/2045125316681984","journal-title":"Ther Adv Psychopharmacol"},{"key":"783_CR6","volume-title":"Richtlinie der Bundes\u00e4rztekammer zur Durchf\u00fchrung der substitutionsgest\u00fctzten Behandlung Opioidabh\u00e4ngiger","author":"Bundes\u00e4rztekammer","year":"2017","unstructured":"Bundes\u00e4rztekammer (2017) Richtlinie der Bundes\u00e4rztekammer zur Durchf\u00fchrung der substitutionsgest\u00fctzten Behandlung Opioidabh\u00e4ngiger. \n                    www.bundesaerztekammer.de\/fileadmin\/user_upload\/downloads\/pdf-Ordner\/RL\/Substitution.pdf\n                    \n                  . Zugegriffen: 28. Mai 2019"},{"key":"783_CR7","volume-title":"National survey on drug use and health: detailed tables. Substance abuse and mental health services administrations","author":"Center for Behavioral Health Statistics and Quality (CBHSQ)","year":"2016","unstructured":"Center for Behavioral Health Statistics and Quality (CBHSQ) (2016) National survey on drug use and health: detailed tables. Substance abuse and mental health services administrations. SAMHSA, Rockville"},{"key":"783_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1300\/J069v20n04_02","volume":"20","author":"RL Deamer","year":"2001","unstructured":"Deamer\u00a0RL, Wilson\u00a0DR, Clark\u00a0DS, Prichard\u00a0JG (2001) Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM). J\u00a0Addict Dis 20:7\u201314. \n                    https:\/\/doi.org\/10.1300\/J069v20n04_02","journal-title":"J Addict Dis"},{"issue":"8","key":"783_CR9","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/add.12551","volume":"109","author":"L Degenhardt","year":"2014","unstructured":"Degenhardt\u00a0L, Charlson\u00a0F, Mathers\u00a0B, Hall\u00a0WD, Flaxman\u00a0AD, Johns\u00a0N et\u00a0al (2014) The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction 109(8):1320\u20131333","journal-title":"Addiction"},{"issue":"2","key":"783_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/ADM.0000000000000193","volume":"10","author":"K Dugosh","year":"2016","unstructured":"Dugosh\u00a0K, Abraham\u00a0A, Seymour\u00a0B, McLoyd\u00a0K, Chalk\u00a0M, Festinger\u00a0D (2016) A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of Opioid addiction. J\u00a0Addict Med 10(2):93\u2013103","journal-title":"J Addict Med"},{"issue":"2","key":"783_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1176\/appi.ajp.2007.06111851","volume":"165","author":"L Dutra","year":"2008","unstructured":"Dutra\u00a0L, Stathopoulou\u00a0G, Basden\u00a0SL, Leyro\u00a0TM, Powers\u00a0MB, Otto\u00a0MW (2008) A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 165(2):179\u2013187","journal-title":"Am J Psychiatry"},{"key":"783_CR12","unstructured":"European Agency for the Evaluation of Medical Products (2001). EMEA public statement to suspend the marketing authorisation for Orlaam (levoacetylmethadol) in the European Union. EMEA\/8776\/01."},{"key":"783_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/10550887.2011.642758","volume":"31","author":"A Fareed","year":"2012","unstructured":"Fareed\u00a0A, Vayalapalli\u00a0S, Casarella\u00a0J, Drexler\u00a0K (2012) Effect of buprenorphine dose on treatment outcome. J\u00a0Addict Dis 31:8\u201318","journal-title":"J Addict Dis"},{"key":"783_CR14","volume-title":"Probuphine\u2122 prescribing information","author":"US Food and Drug Administration","year":"2016","unstructured":"US Food and Drug Administration (2016) Probuphine\u2122 prescribing information. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/204442Orig1s000lbl.pdf"},{"key":"783_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","volume":"144","author":"MK Greenwald","year":"2014","unstructured":"Greenwald\u00a0MK, Comer\u00a0SD, Fiellin\u00a0DA (2014) Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend 144:1\u201311","journal-title":"Drug Alcohol Depend"},{"key":"783_CR16","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","volume":"28","author":"MK Greenwald","year":"2003","unstructured":"Greenwald\u00a0MK, Johanson\u00a0CE, Moody\u00a0DE et al (2003) Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28:2000\u20132009","journal-title":"Neuropsychopharmacology"},{"key":"783_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jsat.2017.04.008","volume":"78","author":"C Haasen","year":"2017","unstructured":"Haasen\u00a0C, Linden\u00a0M, Tiberg\u00a0F (2017) Pharmacokinetics and pharmacodynamics of a\u00a0buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid disorder. J\u00a0Subst Abuse Treat 78:22\u201329","journal-title":"J Subst Abuse Treat"},{"issue":"10173","key":"783_CR18","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","volume":"393","author":"BR Haight","year":"2019","unstructured":"Haight\u00a0BR, Learned\u00a0SM, Laffont\u00a0CM, Fudala\u00a0J, Zhao\u00a0Y, Garofalo\u00a0AS, Greenwald\u00a0MK, Nadipelli\u00a0VR, Ling\u00a0W, Heidbrder\u00a0C, RB-US-13-0001 Study Investigators (2019) Efficacy and safety of a\u00a0monthly buprenorphine depot injection for opioid use disorder: a\u00a0multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 393(10173):778\u2013790. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(18)32259-1","journal-title":"Lancet"},{"key":"783_CR19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/add.13238","volume":"111","author":"YI Hser","year":"2016","unstructured":"Hser\u00a0YI, Evans\u00a0E, Huang\u00a0D et al (2016) Long-term outcomes after randomization to buprenorphiine\/naloxone versus methadone in a\u00a0multi-site trial. Addiction 111:695\u2013705","journal-title":"Addiction"},{"key":"783_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/ADM.0000000000000274","volume":"11","author":"YI Hser","year":"2017","unstructured":"Hser\u00a0YI, Huang\u00a0D, Saxon\u00a0AJ et al (2017) Distinctine trajectories of opioid use over an extended follow-up of patients in a\u00a0multisite trial on buprenorphine+naloxone and methadone. J\u00a0Addict Med 11:63\u201369","journal-title":"J Addict Med"},{"key":"783_CR21","first-page":"8","volume":"109","author":"YI Hser","year":"2014","unstructured":"Hser\u00a0YI, Saxon\u00a0AJ, Huang\u00a0D et al (2014) Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a\u00a0multi-site trial. Addiction 109:8\u201318","journal-title":"Addiction"},{"key":"783_CR22","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.2147\/DDDT.S109331","volume":"11","author":"M Itzoe","year":"2017","unstructured":"Itzoe\u00a0M, Guarnieri\u00a0M (2017) New developments in managing opioid addiction: impact of a\u00a0subdermal buprenorphine implant. Drug Des Devel Ther 11:1429\u20131437. \n                    https:\/\/doi.org\/10.2147\/DDDT.S109331","journal-title":"Drug Des Devel Ther"},{"key":"783_CR23","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1001\/jama.1992.03480200058024","volume":"267","author":"RE Johnson","year":"1992","unstructured":"Johnson\u00a0RE, Jaffe\u00a0JH, Fudala\u00a0PJ (1992) A controlled trial of buprenorphine treatment for opioid dependence. JAMA 267:2750\u20132755","journal-title":"JAMA"},{"key":"783_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jsat.2018.08.011","volume":"94","author":"SR Kenney","year":"2018","unstructured":"Kenney\u00a0SR, Anderson\u00a0BJ, Bailey\u00a0GL, Stein\u00a0MD (2018) Buprenorphine treatment formulations: preferences among persons in opioid withdrawal management. J\u00a0Subst Abuse Treat 94:55\u201359. \n                    https:\/\/doi.org\/10.1016\/j.jsat.2018.08.011","journal-title":"J Subst Abuse Treat"},{"key":"783_CR25","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/jcph.665","volume":"56","author":"CM Laffont","year":"2016","unstructured":"Laffont\u00a0CM, Gomeni\u00a0R, Heidbreder\u00a0C, Jones\u00a0JP 3rd, Nasser\u00a0AF (2016) Population Pharmacokinetic modeling after repeated administrations of RBP-6000, a\u00a0new, subcutaneously Injectable, long-acting, sustained-release formulation of Buprenorphine, for the treatment of Opioid use disorder. J\u00a0Clin Pharmacol 56:806\u2013815","journal-title":"J Clin Pharmacol"},{"key":"783_CR26","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","volume":"93","author":"W Ling","year":"1998","unstructured":"Ling\u00a0W, Charuvastra\u00a0C, Collins\u00a0JF et\u00a0al (1998) Buprenorphine maintenance treatment of opiate dependence: a\u00a0multicenter, randomized clinical trial. Addiction 93:475","journal-title":"Addiction"},{"key":"783_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000517","author":"W Ling","year":"2019","unstructured":"Ling\u00a0W, Nadipelli\u00a0VR, Solem\u00a0CT, Ronquest\u00a0NA, Yeh\u00a0YC, Learned\u00a0SM, Mehra\u00a0V, Heidbreder\u00a0C (2019) Patient-centered outcomes in participants of a\u00a0Buprenorphine monthly depot (BUP-XR) double-blind, placebo-controlled, Multicenter, phase 3 study. J\u00a0Addict Med. \n                    https:\/\/doi.org\/10.1097\/ADM.0000000000000517","journal-title":"J Addict Med"},{"key":"783_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","volume":"8","author":"MR Lofwall","year":"2014","unstructured":"Lofwall\u00a0MR, Walsh\u00a0SL (2014) A review of buprenorphine diversion and misuse: the current evidence base and experience from around the world. J\u00a0Addict Med 8:315\u2013326","journal-title":"J Addict Med"},{"key":"783_CR29","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","volume":"178","author":"MR Lofwall","year":"2018","unstructured":"Lofwall\u00a0MR, Walsh\u00a0SL, Nunes\u00a0EV, Bailey\u00a0GL, Sigmon\u00a0SC, Kampman\u00a0KM, Frost\u00a0M, Tiberg\u00a0F, Linden\u00a0M, Sheldon\u00a0B, Oosman\u00a0S, Peterson\u00a0S, Chen\u00a0M, Kim\u00a0S (2018) Weekly and monthly subcutaneous Buprenorhpine depot formulations vs daily Sublingual Burpenorphine with Naloxone for treatment of Opioid use disorder: a randomized clinical trial. JAMA Intern Med 178:764\u2013773","journal-title":"JAMA Intern Med"},{"key":"783_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","author":"RP Mattick","year":"2014","unstructured":"Mattick\u00a0RP, Breen\u00a0C, Kimber\u00a0J, Davoli\u00a0M (2014) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev CD002207. \n                    https:\/\/doi.org\/10.1002\/14651858.CD002207.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"783_CR31","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40262-014-0155-0","volume":"53","author":"AF Nasser","year":"2014","unstructured":"Nasser\u00a0AF, Heidbreder\u00a0C, Gomeni\u00a0R, Fudala\u00a0PJ, Zheng\u00a0B, Greenwald\u00a0MK (2014) A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a\u00a0new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. Clin Pharmacokinet 53:813\u2013824","journal-title":"Clin Pharmacokinet"},{"key":"783_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/JCP.0000000000000434","volume":"36","author":"AF Nasser","year":"2016","unstructured":"Nasser\u00a0AF, Greenwald\u00a0MK, Vince\u00a0B, Fudala\u00a0PJ, Twumasi-Ankrah\u00a0P, Liu\u00a0Y, Jones\u00a0JP 3rd, Heidbreder\u00a0C (2016) Sustained-release Buprenorphine (RBP-6000) blocks the effects of Opioid challenge with Hydromorphone in subjects with Opioid use disorder. J\u00a0Clin Psychopharmacol 36:18\u201326. \n                    https:\/\/doi.org\/10.1097\/JCP","journal-title":"J Clin Psychopharmacol"},{"key":"783_CR33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/add.14442","volume":"114","author":"C Nordt","year":"2019","unstructured":"Nordt\u00a0C, Vogel\u00a0M, Dey\u00a0M, Moldovanyi\u00a0A, Beck\u00a0T, Berthel\u00a0T, Walter\u00a0M, Seifritz\u00a0E, D\u00fcrsteler\u00a0KM, Herdener\u00a0M (2019) One size does not fit all-evolution of opioid agonist treatments in a\u00a0naturalistic setting over 23 years. Addiction 114:103\u2013111. \n                    https:\/\/doi.org\/10.1111\/add.14442","journal-title":"Addiction"},{"key":"783_CR34","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1001\/jama.2016.9382","volume":"316","author":"RN Rosenthal","year":"2016","unstructured":"Rosenthal\u00a0RN, Lofwall\u00a0MR, Kim\u00a0S, Chen\u00a0M, Beebe\u00a0KL, Vocci\u00a0FJ, PRO-814 Study Group (2016) Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a\u00a0randomized clinical traial. JAMA 316:282\u2013290","journal-title":"JAMA"},{"key":"783_CR35","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1111\/add.12315","volume":"108","author":"RN Rosenthal","year":"2013","unstructured":"Rosenthal\u00a0RN, Ling\u00a0W, Casadonte\u00a0P et\u00a0al (2013) Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine\/naloxone. Addiction 108:2141\u20132149","journal-title":"Addiction"},{"key":"783_CR36","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1001\/archpsyc.1997.01830200041006","volume":"54","author":"RS Schottenfeld","year":"1997","unstructured":"Schottenfeld\u00a0RS, Pakes\u00a0JR, Oliveto\u00a0A, Ziedonis\u00a0D, Kosten\u00a0TR (1997) Buprenorphine vs methadone maintenance treatment for concurrent opiod dependence and cocaine abuse. Arch Gen Psychiatry 54:713\u2013720","journal-title":"Arch Gen Psychiatry"},{"key":"783_CR37","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1056\/NEJMra1604339","volume":"375","author":"MA Schuckit","year":"2016","unstructured":"Schuckit\u00a0MA (2016) Treatment of opioid-use disorders. N\u00a0Engl J Med 375:1596\u20131597","journal-title":"N Engl J Med"},{"key":"783_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1406","author":"VD Schmith","year":"2019","unstructured":"Schmith\u00a0VD, Curd\u00a0L, Lohmer\u00a0LRL, Laffont\u00a0CM, Andorn\u00a0A, Young\u00a0MA (2019) Evaluation of the effects of a\u00a0monthly buprenorphine depot subcutaneous injection on qt interval during treatment for opioid use disorder. Clin Pharmacol Ther. \n                    https:\/\/doi.org\/10.1002\/cpt.1406","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"783_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000468518","volume":"23","author":"M Soyka","year":"2017","unstructured":"Soyka\u00a0M, Strehle\u00a0J, Rehm\u00a0J, B\u00fchringer\u00a0G, Wittchen\u00a0H\u2011U (2017) Six-year outcome of Opioid maintenance treatment in heroin-dependent patients: results from a\u00a0naturalistic study in a\u00a0nationally representative sample. Eur Addict Res 23(2):97\u2013105","journal-title":"Eur Addict Res"},{"issue":"1","key":"783_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","volume":"35","author":"C Timko","year":"2016","unstructured":"Timko\u00a0C, Schultz\u00a0NR, Cucciare\u00a0MA, Vittorio\u00a0L, Garrison-Diehn\u00a0C (2016) Retention in medication-assisted treatment for opiate dependence: a systematic review. J\u00a0Addict Dis 35(1):22\u201335","journal-title":"J Addict Dis"},{"key":"783_CR41","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMp1402780","volume":"370","author":"ND Volkow","year":"2014","unstructured":"Volkow\u00a0ND, Frieden\u00a0TR, Hyde\u00a0PS, Cha\u00a0SS (2014) Medication-Assisted therapies: tackling the opioid-overdose epidemic. N\u00a0Engl J Med 370:2063\u20132066","journal-title":"N Engl J Med"},{"key":"783_CR42","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1001\/jamapsychiatry.2017.1874","volume":"74","author":"SL Walsh","year":"2017","unstructured":"Walsh\u00a0SL, Comer\u00a0SD, Lofwall\u00a0MR et\u00a0al (2017) Effect of buprenorphine weekly depot (CAM 2038) and hydromorphone blockade in individuals with opioid use disorder: a\u00a0randomized clinical trial. JAMA Psychiatry 74:894\u2013902. \n                    https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.1874","journal-title":"JAMA Psychiatry"},{"key":"783_CR43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/B978-3-437-23021-9.00010-2","volume-title":"Suchtmedizin","author":"M Walter","year":"2019","unstructured":"Walter\u00a0M, Soyka\u00a0M (2019) Opioide. In: Soyka\u00a0M et\u00a0al (Hrsg) Suchtmedizin. Elsevier, M\u00fcnchen, S\u00a0177\u2013202"},{"key":"783_CR44","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.drugalcdep.2009.03.008","volume":"103","author":"J White","year":"2009","unstructured":"White\u00a0J, Bell\u00a0J, Saunders\u00a0JB, Williamson\u00a0P, Makowska\u00a0M, Farquharson\u00a0A, Beebe\u00a0KL (2009) Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend 103:37\u201343. \n                    https:\/\/doi.org\/10.1016\/j.drugalcdep.2009.03.008","journal-title":"Drug Alcohol Depend"},{"key":"783_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2047-783X-14-1-7","volume":"14","author":"H Wieneke","year":"2009","unstructured":"Wieneke\u00a0H, Conrads\u00a0H, Wolstein\u00a0J, Breuckmann\u00a0F, Gastpar\u00a0M, Erbel\u00a0R, Scherbaum\u00a0N (2009) Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation\u2014results from a\u00a0controlled clinical trial. Eur J Med Res 14:7\u201312","journal-title":"Eur J Med Res"},{"key":"783_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0028-1083818","volume":"42","author":"J Wolstein","year":"2009","unstructured":"Wolstein\u00a0J, Gastpar\u00a0M, Finkbeiner\u00a0T, Heinrich\u00a0C, Heitkamp\u00a0R, Poehlke\u00a0T, Scherbaum\u00a0N (2009) A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction. Pharmacopsychiatry 42:1\u20138. \n                    https:\/\/doi.org\/10.1055\/s-0028-1083818","journal-title":"Pharmacopsychiatry"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-019-0783-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-019-0783-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-019-0783-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T23:32:43Z","timestamp":1596843163000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-019-0783-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["783"],"URL":"https:\/\/doi.org\/10.1007\/s00115-019-0783-6","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,9]]},"assertion":[{"value":"9 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Soyka und O.\u00a0Pogarell geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}